Dendreon is a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy. Dendreon’s flagship product, PROVENGE (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells. More than 40,000 men with advanced prostate cancer have been prescribed PROVENGE in the U.S. since 2010. Dendreon also is evaluating the use of PROVENGE in early-stage prostate cancer, with the hope of curing more men of the disease. Dendreon is headquartered in Seal Beach, Calif.
View Top Employees from DendreonWebsite | http://www.dendreon.com |
Revenue | $284 million |
Funding | $50 million |
Employees | 671 (671 on RocketReach) |
Founded | 1992 |
Address | 1700 Saturn Way, Seal Beach, California 90740, US |
Phone | (562) 252-7500 |
Fax | (206) 256-0571 |
Technologies |
JavaScript,
HTML,
Google Analytics
+78 more
(view full list)
|
Industry | Biotechnology Research, Drug Manufacturing & Research, Biotechnology, Oncology, Pharmaceuticals, Drug Discovery, Healthcare |
Web Rank | 804175 |
Keywords | Cancer Treatment, Prostate Cancer Treatment |
Competitors | Agenus, Avanir Pharmaceuticals, BioNTech SE, MacroGenics, Inc., Sorrento Therapeutics, Inc. |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Dendreon employee's phone or email?
The Dendreon annual revenue was $284 million in 2024.
Michael Allen is the Vice president, Information Technology of Dendreon.
671 people are employed at Dendreon.
Dendreon is based in Seal Beach, California.
The NAICS codes for Dendreon are [3254, 32541, 325, 32].
The SIC codes for Dendreon are [28, 283].